Treatment Profiles of Hypertensive Patients at a Private Hospital in Cirebon

Background: Hypertension is one of the most widely prevalent cardiovascular disorders in the world, affecting 1.28 billion adults, of whom two-thirds live in low- and middle-income countries. Objectives: To assess the distribution of hypertensive patients receiving monotherapy, dual combination, and triple combination antihypertensive medication and its comorbidities. Methods: This descriptive analytic study was conducted from November 2022 to November 2023. This study included adult hypertensive patients (age ≥18 years) treated with one or more antihypertensive medications. The hospital information system was used to obtain demographic and clinical data. A total of 147 patients’ data were analyzed. Results: This study shows 42.2% of hypertensive patients are treated with triple combination drugs, 41.5% are receiving four combination drugs, and 4.1% are on five antihypertension drugs. Only 2.7% are receiving monotherapy, and 9.5% of patients are receiving dual combination drugs. The most commonly used triple combination drugs (35.5%) are angiotensin receptor blocker (ARB), dihydropyridine-calcium channel blocker (DHP-CCB), and beta blocker (BB). BB is one of the most used antihypertension drugs (86.4%), beside DHP-CCB (87%). Most patients receiving triple combination drugs are women (85.5%), in the age group between 55 and 64 years old (46.8%), and 69.3% have coronary artery disease (CAD) as the most prevalent comorbidity. Conclusion: Most hypertensive patients are receiving triple combination drugs as their daily antihypertension therapy, with BB being one of the most used antihypertension drugs. Most of these patients have CAD as a comorbidity. The most frequently used drugs are in accordance with the recent hypertension guidelines.